text
"['\n7. 핵심 연구인력(상세)\n☞ 본문 위치로 이동\n직위\n성명\n담당업무\n주요경력\n주요 연구실적*\n부사장\n최성구\nResearch & Development\n\xa0서울대 의학과 졸업 \xa0충북대 의학과 석사 \xa0한국얀센(00~15) \xa0국립정신건강세터 의료부장(15~17) \xa0일동제약 연구소장(17~현재)\n[논문] \xa01. Changes in use of antipsychotics in patients with schizophrenia and factors affecting the use of typical drugs in Korea(18년, BMJ Open) \xa02. Risk factors for relapse in patients with first-episode schizophrenia: Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015(18년, Int J Ment Health Syst) \xa03. Mental health services and R&D in South(16년, Int J Ment Health Syst) \xa04. Effect of the Apoprotein E epsilon4 Allele on the efficacy and Tolerability of Galantamine in the Treatment of Alzheimer’s disease(05년, Dement Geriatr Cogn Disord) \xa05. 외 다수.(20편 이상)\n부장\n박진경\nClinical Intelligence\xa0\n한국외대 통계학과 졸업 한국외대 통계학 석사 한국외대 통계학 박사 한국외대 강사 (1997~2015) 서울대학교 보건대학원 강사 (2019)  한국외대 겸임교수(2020~2021) 국제백신 연구소 Sr.Biostatistian(2001~2016)  일동제약 CI 팀장(2016~ )\xa0\n[논문] 1. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study (2017, Lancet Glob Health)  2. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment (2014, Lancet Glob Health)  3. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial (2013, The Lancet Infectious Diseases) 4. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial (2009, The Lancet)  5. A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India (2009, NEJM)  6. 외 다수(40편 이상)  [출판] 1. SPSS 통계분석 (자유아카데미) 초판 ~ 제5판 (2019)\xa0\n수석연구원\n반홍석\nImmuno-Cytokine Research\n한양대 생화학과졸업 한양대 생명공학과 석사 한양대 생명공학과 박사 일동제약 선임연구원(13~19) 일동제약 CIIC팀장(20~현재)\n[논문] 1.T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice(08년, Cell) 2. The heat shock protein 27 (Hsp27) operates predominantly by blocking the mitochondrial-independent/extrinsic pathway of cellular apoptosis(09년, Mol cells) 3. Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery(09년, J Control Release) 4. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles(12년, Bioconjug chem) 5. Attachment of cell-binding ligands to arginine-rich cell-penetrating peptides enables cytosolic translocation of complexed siRNA(15년, Chem Biol)\xa0\n수석연구원\n안경미\nMedicinal Chemistry\n이화여대 화학과 졸업 이화여대 분자생명과학부 석사 (유기의약화학 전공) 이화여대 화학,나노과학과 박사 (유기의약화학 전공) 일동제약 (02~현재) 일동제약 MC팀장 (20~현재)\n[학회 발표] 1. Discovery of ID11014A as a Novel GPR40 Agonist for the Treatment of Type 2 Diabetes (17년, ADA-poster) 2. Preclinical Development of IDG-16177 as a Potent GPR40 agonist for Treatment of Type 2 Diabetes (20년, ADA-poster) [논문] 1. Development of stroke Therapy: A study on the synergy effects of nitrone compounds with ZBD (석사학위) 2. Discovery of GPR40 agonists as Potent Antidiabetic agents (박사학위) 3. Synthesis and Biological Evaluation of N-Formyl Hydroxylamine Derivatives as Potent Peptide Deformylase Inhibitors (Bull. Korean Chem. Soc. 2006, 27, 7, 1075) 4. Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria (Bioorg. Med. Chem. Lett. 2016, 26, 3148) 5. 3-Aryl-3-(isoxazol-3-yl)propanoic Acids and 2-Aryloxyacetic Acids as Potent GPR40 Agonists (Bull. Korean Chem. Soc. 2017, 38, 838) 6. Discovery of 2,3-Dihydro-1H-indene Derivatives as Novel GPR40 Agonists (Bull. Korean Chem. Soc. 2017, 38, 861) [특허] 1. 신규 페닐 프로피온 산 유도체 및 이의 용도 (KR10-2016-0171541) 2. 신규한 페닐 프로피온 산 GPR40 효현제 (KR10-2016-0176546) 3. GLP-1 수용체 작용제 및 이의 용도 (KR10-2019-0146798, KR10-2020-0022485) 4. 신규한 산 분비 억제제 및 이의 용도 (KR10-2020-0073900)\n수석연구원\n윤홍철\nInnovative Solution\n고려대 생물공학 졸업 고려대 생화학 석사 연세대 의약화학 박사 대웅제약 수석연구원(10~12) CalIBR (California Institute for Biomedical Research,San Diego) Research scientist(12~15) 일동제약 수석연구원(16~현재) 일동제약 ISG그룹장(20~현재)\xa0\n[논문] 1. Property based optimization of δ-lactam HDAC inhibitors for metabolic stability: Bioorganic & Medicinal Chemistry Letter, 2010, 20, 6808-6811  2. Structure Based Optimization of Chromen-Based TNF-α Converting Enzyme (TACE) Inhibitors on S1’ Pocket and Their Quantitative Structure Activity Relationship Study: Bioorganic medicinal chemistry , 2010, 18, 8618-8629  [특허] 1. 대한민국 특허출원 10-2019-0146798 ""GLP-1 수용체 작용제 및 이의 용도"" Nov.19, 2019 2. US patent 9452170 “Compounds inducing chondrogenesis and their preparation” issued date: Sep. 27, 2016 3. European Patent 1861387 “Novel benzoimidazole derivatives and pharmaceutical composition comprising the same” issued date: Apr 16, 2014 4. 외 다수(30건 이상)\n수석연구원\n이상영\nDifferentiated Product Research\n충남대 약학대학 졸업 충남대 약학석사 성균관대 약학박사 일동제약 제제연구팀장(07~18) 일동제약 DP그룹장(19~현재)\n\xa0[논문] \xa01. Pharmacokinetics of a telmisartan, amlodipine and hydrochlorothiazide \xa0fixed-dose combination; A replicate crossover study in healthy Korean male subjects 16(9):2245-2253(2017) \xa02. Formulation of a modified-release pregabalin tablet using hot-melt coating with glyceryl behenate. International Journal of Pharmaceutics 495:1-8 (2015) \xa0[특허] 1. 둘록세틴이 함유된 안정한 다중코팅 정제 조성물(Multicoating pharmaceutical composition containing duloxetin) 2. 안정성이 향상된 복합철분제 및 그 제조방법(Iron-vitamins supplememts with enhanced stability and process for preparing thereof) 3. 보관 안정성이 확보된 고혈압 및 고지혈증 치료용 복합 조성물(Pharmaceutical composition having storage stability for the treatment of hypertension and hyperlipidermia) 4. 흡습성이 개선된 고협압 및 발기부전 치료제를 함유한 약제학적 복합 조성물(Pharmaceutical composition having improved hygroscopicity for the treatment of hypertension and impotence)\n수석연구원\n이정우\nToxicological Research\n경북대 수의학과 졸업 경북대 수의학과 석사 경북대 수의학과 박사 대웅제약 수석연구원(10~16) 일동제약 수석연구원(16~현재) 일동제약 TR팀장 (19~현재)\n[학회발표] 1. Non-Clinical Strategy of Monoclonal Antibody for Ocular Disease (2019 3rd CND TOX BOOTCAMP-Lecture) 2. The effects of haemodialysate solcoseryl and a hydrogel dressing(Nu-Gel) for full-sickness skin wound healing in dogs (The Korean Society of Veterinary Clinics, 2003) [논문] 1. Hemangiosarcoma in a Female Pointer (Journal of veterinary clinics, 2001) 2. The Effecttiveness of the Haemolialysate Solcoseryl for Second-Intention Full-Thickness Skin Wound Healing in Dogs (Korean Journal of veterinary research, 2003) 3. A comparative study of hydrocolloid (Duoderm) and a hydrogel occlusive dressing material(Nu-Gel) in the treatment of full-thickness skin wound in dogs (Journal of veterinary clinics, 2003) 4. Effect of β-Glucan Originated from Aureobasidium on Infected Dermal Wound Healing of the Normal Nude Mouse (Journal of veterinary clinics, 2012) 5. Effect of β-glucan Originated from Aureobasidium on the Dermal Wound Repair in Vitro Model (Journal of veterinary clinics, 2013)\xa0\n수석연구원\n정규호\nPharmaceutical Delivery & Design\n우석대학교 약학과 졸업 우석대학교 약학과 석사 중앙대학교 약학과 박사 일동제약 PDD팀장(19~현재)\n[논문] 1.Formulation of a modified-release pregabalin tablet using hot-melt coating with glyceryl behenate. International Journal of Pharmaceutics 495:1-8 (2015) 2. Nanostructured lipid carrier-loaded hyaluronic acid microneedles for controlled dermal delivery of a lipophilic molecule. International Journal of \xa0Nanomedicine 9:289-299 (2014) 3. Pharmacokinetics of a telmisartan/amlodipine/hydrochlorothiazide fixed-dose combination: a replicate crossover study in healthy korean male subjects. Tropical Journal of Pharmaceutical Research,16 (9): 2245-2253(2017)  [특허] 1. 둘록세틴이 함유된 안정한 다중코팅 정제 조성물(Multicoating pharmaceutical composition containing duloxetin) 2.베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법(Granules comprising besifovir dipivoxil or pharmaceutical acceptable salts thereof, a pharmaceutical composition comprising the same and a method for preparing the same) 3. 흡습성이 개선된 고협압 및 발기부전 치료제를 함유한 약제학적 복합 조성물(Pharmaceutical composition having improved hygroscopicity for the treatment of hypertension and impotence)\n수석연구원\n이성희\nMICROBIOME Research and Development\n순천향대학교 유전공학과 졸업 서울대학교 보건대학원 석사 서울대학교 보건대학원 박사 일동제약 선임연구원(17~20) 일동제약 MIOM팀장(21~현재)\n[논문] 1. Altered Gut Microbiota in Korean Children with Autism Spectrum Disorders (21년, Nutrients) 2. Community State Types of Vaginal Microbiota and Four Types of Abnormal Vaginal Microbiota in Pregnant Korean Women (20년, Front Public Health) 3. Gene-targeted metagenomic analysis of glucan-branching enzyme gene profiles among human and animal fecal microbiota. \xa0(14년, ISME J) 4. Comparison of the gut microbiotas of healthy adult twins living in South Korea and the United States. (11년, Appl Environ Microbiol) 5. Genome sequence of Lactobacillus ruminis SPM0211, isolated from a fecal sample from a healthy Korean. (11년, J Bacteriol) 6. 외 다수.(20편 이상) [특허] 1. 락토바실러스 속 균주 및 이를 포함하는 질염의 예방 또는 치료용 조성물 2. 매트릭스 캡슐 보호막 자연 생성 기술을 통한 유산균의 동결건조 생존율, 열 저항성, 저장 안정성 및 체내 안정성이 향상된 캡슐화 프로바이오틱스의 논스톱 제조 공정 3. 항비만 활성을 갖는 엔테로코커스 락티스 IDCC 2105 및 이의 용도 4. 면역증강 활성을 갖는 프로바이오틱스 균주 및 이의 용도 5. 비피도박테리움 브레베 균주 및 이를 포함하는 NAD+ 및 총 NAD 증진용 조성물\n수석연구원\n이진희\xa0\nArtificial Intelligence\n인하대 화학과 졸업 인하대 화학과 석사 이화여대 약학과 박사 JW중외제약(11~17) 일동제약 책임연구원 (17~22) 일동제약 AI팀장 (23~현재)\n[논문] 1. Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary, Journal of Medicinal Chemistry, 2021, 64, 12525?1253 2. Discovery of μ,δ-Opioid Receptor Dual-Biased Agonists That Overcome the Limitation of Prior Biased Agonists, ACS Pharmacology & Translational Science, 2021, 4, 1149-1160 3. Structural insights into transient receptor potential vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and mutational studies, Journal of Computer-Aided Molecular Design, 2011, 25, 317-327  4. In silico classification of adenosine receptor antagonists using Laplacian-modified naive Bayesian, support vector machine, and recursive partitioning, Journal of Molecular Graphics and Modelling, 2010, 28, 883?890.  5. 외 다수(13편)\n']"
